In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors

We measured the uptake of the somatostatin receptor ligand 68Ga-[1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE) in the left anterior descending coronary artery (LAD) in association with calcified plaques (CPs) and cardiovascular risk factors. Methods: Seventy consecutive tumor patients were examined by whole-body 68Ga-DOTATATE contrast-enhanced PET/CT. Blood-pool–corrected standardized uptake value (target-to-background ratio) was measured in the LAD, and CT images were used to detect CP. Cardiovascular risk factors and history of prior cardiovascular events were recorded. Results: 68Ga-DOTATATE uptake was detectable in the LAD of all patients. Target-to-background ratio in the LAD correlated significantly with the presence of CP (R = 0.34; P < 0.01), prior vascular events (R = 0.26; P < 0.05), and male sex (R = 0.29; P < 0.05), whereas CP correlated with these parameters but also with age (R = 0.34; P < 0.01) and hypertension (R = 0.25; P < 0.05). Conclusion: In a series of oncologic patients, those with prior cardiovascular events and calcified atherosclerotic plaques showed significantly increased 68Ga-DOTATATE uptake in the LAD, suggesting a potential role of this tracer for plaque imaging in the coronary arteries.

[1]  R. Virmani,et al.  Culprit plaque in myocardial infarction going beyond angiography. , 2007, Journal of the American College of Cardiology.

[2]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[3]  O. Schober,et al.  Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  M. Reiser,et al.  18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease , 2009, Journal of Nuclear Medicine.

[5]  V. Fuster,et al.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. , 2007, Journal of the American College of Cardiology.

[6]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[7]  Bernd J Pichler,et al.  Radionuclide imaging: a molecular key to the atherosclerotic plaque. , 2008, Journal of the American College of Cardiology.

[8]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[9]  Daniel S Berman,et al.  Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. , 2007, Journal of the American College of Cardiology.

[10]  Sameer Bansilal,et al.  Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations , 2008, Journal of Nuclear Medicine.

[11]  A. Alavi,et al.  18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. , 2002, Seminars in nuclear medicine.

[12]  Marc Faraggi,et al.  Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events , 2008, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[13]  V. Fuster,et al.  Angiographic progression of coronary artery disease and the development of myocardial infarction. , 1988, Journal of the American College of Cardiology.

[14]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[15]  Ahmed Tawakol,et al.  In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. , 2006, Journal of the American College of Cardiology.

[16]  J. Wykrzykowska,et al.  Imaging of Inflamed and Vulnerable Plaque in Coronary Arteries with 18F-FDG PET/CT in Patients with Suppression of Myocardial Uptake Using a Low-Carbohydrate, High-Fat Preparation , 2009, Journal of Nuclear Medicine.

[17]  Ora Israel,et al.  Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  A. Balbarini,et al.  Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages , 2007, Journal of leukocyte biology.

[19]  Marion de Jong,et al.  Radiolabelling DOTA-peptides with 68Ga , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  J. Li,et al.  SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN‐γ release , 1999, European journal of immunology.

[21]  M. Daemen,et al.  Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. , 2004, The New England journal of medicine.

[22]  W. Kerwin,et al.  The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. , 2007, Radiology.